Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer-Reference-Cited by-同舟云学术

Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer

Published:2023-10-05 Issue:20 Volume:66 Page:14150-14174
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhao Chunlong¹^ORCID,Zhang Yu²,Zhang Jin’ge²,Li Shunda¹,Liu Mengyang²,Geng Yinping²,Liu Fengling¹,Chai Qipeng¹,Meng Hongwei¹,Li Mengzhe¹,Li Jintao¹,Zheng Yichao²^ORCID,Zhang Yingjie¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Ji’nan, Shandong 250012, P.R. China

2. Key Lab of Advanced Drug Preparation Technologies (Ministry of Education), State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China

Funder

Zhengzhou University

Education Department of Henan Province

Shandong University

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Youth Supporting Program from Henan Province

Basic and Frontier Technology Research Project of Henan Province

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine